Investorideas.com

Get great ideas from our AI, cannabis, cleantech, crypto, esports and mining podcasts - be a guest or sponsor : 800 665 0411

 


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology, telemedicine, Covid-19

Like Biotech Stocks? View our Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech stocks - Feature Your Company & Product Here

Biotech News

#Medtech Stocks in the News: Electromedical Technologies (OTCQB: $EMED) Produces $4.2 Million in Device Inventory to Meet Demand
SCOTTSDALE, Ariz. - November 20, 2020 (Investorideas.com Newswire) Breaking Medical Technology stock news - Electromedical Technologies, Inc. ( OTCQB: EMED ) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that the company has completed the production of over 1,200 units of its FDA cleared bioelectronic chronic pain solution WellnessPro+ device representing approximately $4.2 million of inventory to meet demand.

Kodiak Sciences Announces Pricing of $560.9 Million Common Stock Offering
November 19, 2020 (Investorideas.com Newswire) Kodiak Sciences shares reached a new 52-week high after the company announced the pricing of a $560.9 million public offering of its common stock.

Biotech Stock News: NervGen Pharma (TSXV: NGEN) (OTCQX: NGENF) Reports Third Quarter 2020 Results and Provides Operational Update
Vancouver, British Columbia - November 19, 2020 (Newsfile Corp.) (Investorideas.com Newswire) NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 30, 2020.

Medical Technology Stock News: Electromedical Technologies (OTCQB: $EMED) Produces $4.2 Million in Device Inventory to Meet Demand
SCOTTSDALE, Ariz. - November 19, 2020 (Investorideas.com Newswire) Breaking Medical Technology stock news - Electromedical Technologies, Inc. ( OTCQB: EMED ) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that the company has completed the production of over 1,200 units of its FDA cleared bioelectronic chronic pain solution WellnessPro+ device representing approximately $4.2 million of inventory to meet demand.

Lexicon Shares Rise 40% upon Achieving Primary Endpoints in Two Phase 3 Heart Failure Studies
November 18, 2020 (Investorideas.com Newswire) Shares of Lexicon Pharmaceuticals traded higher after the company published results from the Phase 3 SOLOIST and SCORED trials showing that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalization and urgent visits.

Coronavirus / Biotech Stock News Bites: Moderna's (NASDAQ: $MRNA) COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
CAMBRIDGE, Mass - November 16, 2020 (Investorideas.com Newswire) Coronavirus / Biotechnology (COVID-19) Stock News Bites - Moderna, Inc., (Nasdaq: MRNA) , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273

Five Prime Shares Triple in Value as Firm Meets All 3 Primary Endpoints in Phase 2 Gastric and GEJ Cancer Trial
November 12, 2020 (Investorideas.com Newswire) Five Prime Therapeutics shares traded 250% higher after the firm reported topline data from its Phase 2 FIGHT study of bemarituzumab in combination with chemotherapy demonstrated significant progression-free and overall survival rates in advanced gastric and gastroesophageal junction cancer.

Biopharma Posts 'Impressive' Q3/20 Sales Amid Pandemic
November 12, 2020 (Investorideas.com Newswire) Paratek Pharmaceuticals' recent and future revenue are discussed in an H.C. Wainwright & Co. report.

Draganfly Screening Technology Battles Campus, Public Facilities Health Challenges
November 10, 2020 (Investorideas.com Newswire) Knox Henderson delves into how Draganfly's cutting-edge technology is making it possible for universities and other organizations to operate safely during the pandemic.

Pfizer and BioNTech Announce Extremely Positive Phase 3 COVID-19 Vaccine Trial Data; Production of 1.3 Billion Doses in 2021 Planned
November 10, 2020 (Investorideas.com Newswire) Pfizer shares traded 9% higher to a new 52-week high after the company reported that interim data from its Phase 3 COVID-19 vaccine trial with BioNTech showed a 90% success rate in participants without prior evidence of SARS-CoV-2 infection.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Related Guest Posts

Buy a guest post on Investorideas.com

Biotech News from Newsfile

RETRANSMISSION: Bee Vectoring Technologies Enters New Phase to Accelerate Revenue Growth in 2021
Mississauga, Ontario and Sacramento, California--(Newsfile Corp. - November 24, 2020) - Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF) (CVE: BEE) (the "Company" or "BVT") today announced it will intensify its near-term direction to accelerate revenue growth in 2021 and focus on sales and marketing in key regions for the upcoming growing season. The Company's long-term strategy and objectives remain consistent with previous guidance."Over the past several years we demonstrated the significant benefits that...

MustGrow Announces Investor Initiatives, Presentation Today at the Future of Food Investment Conference
Saskatoon, Saskatchewan--(Newsfile Corp. - November 24, 2020) - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company", "MustGrow") is pleased to announce its upcoming investor awareness initiatives. MustGrow continues to actively engage its key stakeholders - potential industry partners, shareholders and prospective investors - by increasing awareness of its remarkable natural mustard-derived crop protection products.TODAY: The Future of Food Investment Conference - SnowCap VenturesTuesday, Nov. 24th at 1:50 pm ETInvestors Register HereOne-On-One...

Bee Vectoring Technologies Enters New Phase to Accelerate Revenue Growth in 2021
Mississauga, Ontario and Sacramento, California--(Newsfile Corp. - November 24, 2020) - Bee Vectoring Technologies International Inc. (CSE: BEE) (OTCQB: BEVVF) (CVE: BEE) (the "Company" or "BVT") today announced it will intensify its near-term direction to accelerate revenue growth in 2021 and focus on sales and marketing in key regions for the upcoming growing season. The Company's long-term strategy and objectives remain consistent with previous guidance."Over the past several years we demonstrated the significant benefits...

American Aires Launches 'Lifetune' - a 5G Optimized, Ground-Breaking New Line of EMR Modulation Technology Products for Home, Office & Pets
Toronto, Ontario--(Newsfile Corp. - November 23, 2020) - American Aires Inc. (CSE: WIFI) (the "Company" or "Aires"), a world leader in developing and bringing electromagnetic radiation protection (EMR) products to market, today announced the launch of "LIFETUNE", a revolutionary new line of EMR protection offerings that are optimized for and compatible with 5G. The new Aires devices are available at a variety of affordable price points according to the degree of radiation they...

PreveCeutical Files Provisional Patent Application for its COVID-19 Formulation
Vancouver, British Columbia--(Newsfile Corp. - November 23, 2020) -  PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on November 20, 2020, entitled "Sol-Gel Cannabinoid Formulation and Antiviral Use", application number 20200904291, with the aim of seeking protection for certain cannabinoid formulations and their use in prevention and treatment of COVID-19 caused by SARS-CoV-2 infection.PreveCeutical's Chief Executive Officer,...

Subscribe to Biotech News